Explore more publications!
New Hampshire STEM News
Submit Press Release

New Hampshire STEM News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire STEM News.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 8, 2025

New Webcast Series by AI/R Company Subsidiary Everymind Highlights Real-World Use Cases of Generative AI and Automation with Agentforce
September 8, 2025

New Webcast Series by AI/R Company Subsidiary Everymind Highlights Real-World Use Cases of Generative AI and Automation with Agentforce

Indeterminate GlobeNewswire
Synaptics to demonstrate how AI-native processing enables MSOs and OTT streamers to deliver new features at IBC 2025
September 8, 2025

Synaptics to demonstrate how AI-native processing enables MSOs and OTT streamers to deliver new features at IBC 2025

Indeterminate GlobeNewswire
Dayforce Flex Work Expands Frontline Contingent Workforce Platform
September 8, 2025

Dayforce Flex Work Expands Frontline Contingent Workforce Platform

Indeterminate GlobeNewswire
BUILDTIME LAUNCHES REVOLUTIONARY CONTRACTOR-BUILT TIMEKEEPING PLATFORM AT NECA 2025
September 8, 2025

BUILDTIME LAUNCHES REVOLUTIONARY CONTRACTOR-BUILT TIMEKEEPING PLATFORM AT NECA 2025

Indeterminate GlobeNewswire
Electrify Expo Comes to Chicago for the First Time September 13-14 at NOW Arena, Just Ahead Of The EV Tax Credit Deadline
September 8, 2025

Electrify Expo Comes to Chicago for the First Time September 13-14 at NOW Arena, Just Ahead Of The EV Tax Credit Deadline

Indeterminate GlobeNewswire
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
September 8, 2025

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025

Indeterminate GlobeNewswire
OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025
September 8, 2025

OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025

Indeterminate GlobeNewswire
super{set} Unveils 2025 super{summit} in San Francisco: outside{in} Theme Focuses on AI-Native Company Building
September 8, 2025

super{set} Unveils 2025 super{summit} in San Francisco: outside{in} Theme Focuses on AI-Native Company Building

Indeterminate GlobeNewswire
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
September 8, 2025

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025

Indeterminate GlobeNewswire
BIO CEO John Crowley to Receive Prestigious Dennis K. Stone Award at BioNTX iC³® Summit
September 8, 2025

BIO CEO John Crowley to Receive Prestigious Dennis K. Stone Award at BioNTX iC³® Summit

Indeterminate GlobeNewswire
Society Pass Inc (Nasdaq: SOPA) Maintains Compliance with Nasdaq Continued Listing Requirements
September 8, 2025

Society Pass Inc (Nasdaq: SOPA) Maintains Compliance with Nasdaq Continued Listing Requirements

Indeterminate GlobeNewswire
Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs
September 8, 2025

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Indeterminate GlobeNewswire
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
September 8, 2025

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Indeterminate GlobeNewswire
Dev Barometer: AI Saves Developers Nearly a Full Workday Per Week on Coding
September 8, 2025

Dev Barometer: AI Saves Developers Nearly a Full Workday Per Week on Coding

Indeterminate GlobeNewswire
Youxin Technology Ltd Announces Closing of $6.0 Million Underwritten Public Offering
September 8, 2025

Youxin Technology Ltd Announces Closing of $6.0 Million Underwritten Public Offering

Indeterminate GlobeNewswire
SEALSQ Updates on its Semiconductor Personalization Center Strategy
September 8, 2025

SEALSQ Updates on its Semiconductor Personalization Center Strategy

Indeterminate GlobeNewswire
Anti Capital Adopts Time-Series Database QuestDB to Power Next-Generation Trading Infrastructure
September 8, 2025

Anti Capital Adopts Time-Series Database QuestDB to Power Next-Generation Trading Infrastructure

Indeterminate GlobeNewswire
Novatio Solutions Strengthens European Presence with New Office in Germany
September 8, 2025

Novatio Solutions Strengthens European Presence with New Office in Germany

Indeterminate GlobeNewswire
Freename Introduces .COM Domain Payments Powered by Blockchain-Mirroring Technology
September 8, 2025

Freename Introduces .COM Domain Payments Powered by Blockchain-Mirroring Technology

Indeterminate GlobeNewswire
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 8, 2025

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions